Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.53 ▼ -0.01
(-1.26%)
MKT CAP: $17.7M • VOL: 413.1K
52W L $0 52W H $2
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
JSPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$83.9M | -$76.2M | -$68.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$76 | -$71.3M | -$64.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$77.2M | -$62.6M | -$52.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$77.2M | -$62.6M | -$52.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $28.7M | $71.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.2M | $61.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JSPR.